In ACC tumor samples, all SLC31A1 mutations were copy number amplified (Fig. 4a; Additional file 4: Table S1), which in all tumor samples from TCGA were the most common genetic alterations  in SLC31A1. Besides UCEC and ACC, genetic alteration of SLC31A1 was observed in more than 1% of Bladder Urothelial Carcinoma (BLCA), Prostate, Adenocarcinoma, Sarcoma, and Kidney Renal Papillary Cell Carcinoma. Here, SLC31A1 is linked to sarcoma.